Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
(Date:8/28/2014)... Supplementing their complete line of ... Eppendorf Safe Lock Centrifuge Tubes . This ... quality tubes at an affordable price. Eppendorf Safe ... chemical, medical, pharmaceutical, and life science research and ... able to afford Eppendorf products. , Eppendorf is ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... 1 A new technology known as,ActivePure ... proven in peer-reviewed, published university laboratory studies ... inoculated,surfaces. Recent outbreaks of MRSA in ... parents concerned. Based on NASA research, ...
... Nov. 1 Martek Biosciences,Corporation (Nasdaq: MATK ... United,States District Court in Wilmington, Delaware, has ruled ... injunction in Martek,s favor,against the defendants in the ... Nutrinova Inc. and Nutrinova Nutrition Specialties &,Food Ingredients ...
... ON, Nov. 1 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... following investor conferences in November: Acumen BioFin Rodman ... New York Palace Hotel Tuesday, November 6, 2007 ... Conference, Four Seasons Hotel, Boston Tuesday, November 13, ...
Cached Biology Technology:New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA) 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 3Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences 2Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences 3
(Date:8/27/2014)... is related to ability that we already possess. For ... more easily than learning how to hit a tennis ... Neural Basis of Cognition (CNBC)a joint program between the ... fundamental constraint in the brain that may explain why ... Aug. 28, 2014, issue of Nature , they ...
(Date:8/27/2014)... Athens, Ga. An invasive grass species frequently found ... spiders, who then feed on American toads, a new ... which was accidentally introduced to the U.S. in the ... species and has spread to more than a dozen ... Typically found along roads and in forests, it can ...
(Date:8/27/2014)... When we want to listen carefully to someone, the ... thing we do is stop moving altogether. This strategy ... by our own movements. , This interplay between movement ... brain. Indeed, indirect evidence has long suggested that the ... auditory cortex, which gives rise to our conscious perception ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... environmental enrichment and increased social stress can both affect ... monkey research at Wake Forest University School of Medicine., ... that social rank whether animals are dominant or ... amount of cocaine that monkeys will self-administer. Housed in ...
... Institute (HHMI) researchers have found that rare mutations in ... general population. , The scientists had previously shown that ... rare diseases that are characterized by low blood pressure. ... are participating in the Framingham Heart Study, the researchers ...
... Recent research at Yale provided a glimpse of ... illuminated a relationship between gene processing in humans and ... structure of a crucial self-splicing region of RNA. ... through intermediary RNA molecules. But, after transcription from the ...
Cached Biology News:Environmental enrichment can reduce cocaine use, researchers find 2Rare genetic mutations protect against hypertension 2Rare genetic mutations protect against hypertension 3Rare genetic mutations protect against hypertension 4Yale scientists visualize the machinery of mRNA splicing 2
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects caspase activation by flow cytometry....
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Biology Products: